Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370335 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1ACHECYP3A4 | |
| SCHEMBL3844940 | 0.77 | KDM4E (0.46) | ALDH1A1ACHECYP3A4KDM4EKMT2A | |
| SCHEMBL3844939 | 0.77 | KDM4E (0.46) | ALDH1A1ACHECYP3A4KDM4EKMT2A | |
| SCHEMBL3369853 | 0.75 | MAPT (0.60) | ALDH1A1MAPTMAPK1ACHECYP3A4 | |
| SCHEMBL3369857 | 0.75 | MAPT (0.60) | ALDH1A1MAPTMAPK1ACHECYP3A4 | |
| SCHEMBL31619838 | 0.75 | MAPT (0.60) | ALDH1A1MAPTMAPK1ACHECYP3A4 | |
| SCHEMBL3367895 | 0.73 | KDM4E (0.63) | ALDH1A1ACHECYP3A4KDM4EKMT2A | |
| SCHEMBL3367902 | 0.73 | KDM4E (0.63) | ALDH1A1ACHECYP3A4KDM4EKMT2A | |
| SCHEMBL7569727 | 0.69 | ACHE (0.44) | ALDH1A1MAPK1ACHEKDM4EKMT2A | |
| SCHEMBL23369357 | 0.69 | PDE4A (0.56) | ALDH1A1MAPTMAPK1ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641792-B1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-1641457-B1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20060148840-A1 | Pyrrolodihydroisoquinolines as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1641792-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641457-A1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005002579-A1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003129-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148840-A1 | Pyrrolodihydroisoquinolines as pde10 inhibitors | PDE12, PDE3A, PDE3B | ALDH1A1 848/4885MAPT 3379/4885MAPK1 1915/4885 |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | PDE12, PDE2A, PDE5A | ALDH1A1 665/4885MAPT 1795/4885MAPK1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.